Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$8.86 - $25.04 $2.4 Million - $6.78 Million
270,676 New
270,676 $2.78 Million
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $120,629 - $504,523
6,628 Added 2.16%
313,688 $5.71 Million
Q2 2022

Aug 15, 2022

BUY
$36.28 - $75.29 $683,442 - $1.42 Million
18,838 Added 6.54%
307,060 $15.8 Million
Q1 2022

May 11, 2022

SELL
$69.73 - $142.9 $168,328 - $344,960
-2,414 Reduced 0.83%
288,222 $21.2 Million
Q4 2021

Feb 11, 2022

BUY
$134.56 - $217.97 $265,083 - $429,400
1,970 Added 0.68%
290,636 $41.6 Million
Q3 2021

Nov 12, 2021

BUY
$177.8 - $270.58 $3.17 Million - $4.83 Million
17,852 Added 6.59%
288,666 $59.8 Million
Q2 2021

Aug 11, 2021

SELL
$121.0 - $257.67 $622,908 - $1.33 Million
-5,148 Reduced 1.87%
270,814 $57.5 Million
Q1 2021

May 13, 2021

SELL
$112.98 - $319.93 $2.7 Million - $7.65 Million
-23,913 Reduced 7.97%
275,962 $50 Million
Q4 2020

Feb 09, 2021

BUY
$78.74 - $139.5 $1.34 Million - $2.38 Million
17,052 Added 6.03%
299,875 $33.4 Million
Q3 2020

Nov 12, 2020

SELL
$79.44 - $178.51 $926,349 - $2.08 Million
-11,661 Reduced 3.96%
282,823 $30.6 Million
Q2 2020

Aug 12, 2020

BUY
$13.86 - $83.61 $1.8 Million - $10.9 Million
129,940 Added 78.97%
294,484 $24.5 Million
Q1 2020

May 06, 2020

BUY
$3.93 - $16.0 $140,273 - $571,088
35,693 Added 27.7%
164,544 $2.23 Million
Q4 2019

Feb 14, 2020

SELL
$3.69 - $5.22 $15,605 - $22,075
-4,229 Reduced 3.18%
128,851 $512,000
Q3 2019

Nov 07, 2019

BUY
$4.02 - $7.84 $122,614 - $239,127
30,501 Added 29.73%
133,080 $668,000
Q2 2019

Aug 12, 2019

BUY
$4.93 - $12.2 $505,714 - $1.25 Million
102,579 New
102,579 $601,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.01B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.